VEGFA and nonpapillary renal cell carcinoma: Although anti‐angiogenic therapies targeting VEGF or its receptors have improved outcomes in advanced ccRCC, intrinsic and acquired resistance, as well as limited therapeutic efficacy, remain major clinical challenges.[3, 4, 5] Emerging evidence suggests that post‐transcriptional and post‐translational regulatory mechanisms may contribute to treatment evasion, but the precise molecular underpinnings remain unclear.[6, 7, 8] Thus, elucidating novel pathways governing angiogenesis in ccRCC may provide the foundation for more effective therapeutic strategies.